A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
Most of the cytotoxic chemotherapeutic agents have poor aqueous solubility. These molecules are associated with poor physicochemical and biopharmaceutical properties, which makes the formulation difficult. An important approach in this regard is the use of combination of cyclodextrin and nanotechnology in delivery system. This paper provides an overview of limitations associated with anticancer drugs, their complexation with cyclodextrins, loading/encapsulating the complexed drugs into carriers, and various approaches used for the delivery. The present review article aims to assess the utility of cyclodextrin-based carriers like liposomes, niosomes, nanoparticles, micelles, millirods, and siRNA for delivery of antineoplastic agents. These systems based on cyclodextrin complexation and nanotechnology will camouflage the undesirable properties of drug and lead to synergistic or additive effect. Cyclodextrin-based nanotechnology seems to provide better therapeutic effect and sustain long life of healthy and recovered cells. Still, considerable study on delivery system and administration routes of cyclodextrin-based carriers is necessary with respect to their pharmacokinetics and toxicology to substantiate their safety and efficiency. In future, it would be possible to resolve the conventional and current issues associated with the development and commercialization of antineoplastic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“In passive targeting, liposomes, macromolecular carriers, and nanoparticles exploit the EPR effect, which is a consequence of the increased vasculature permeability and decreased lymphatic function of tumors, to target the drug to the tumor [74].”
BackgroundAmidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Introduction and General Overview of Cyclodextrin Chemistry
Szejtli, J. (1998) · Chemical Reviews · doi:10.1021/cr970022c · Cited by 5,016
Cyclodextrins and their uses: a review
Del Valle, E. M. M. (2004) · Process Biochemistry · doi:10.1016/s0032-9592(03)00258-9 · Cited by 3,375 · cited 1×
“Due to this feature, CDs form inclusion complexes with a wide variety of hydrophobic compounds and change the physicochemical and biological properties of guest molecules [35–38].”
BackgroundNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Improving drug solubility for oral delivery using solid dispersions
Leuner, C. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00076-x · Cited by 2,574
Cyclodextrins and their inclusion complexes
Szejtli, J. (1982) · REAL-EOD (Library of the Hungarian Academy of Sciences and the Information Center Oriental Collection) · Cited by 1,680
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Serajuddin, A. T. M. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js980403l · Cited by 1,648
Solubilizing Excipients in Oral and Injectable Formulations
Strickley, R. G. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016235.32639.23 · Cited by 1,415
Cited by
A Review of Curcumin and Its Derivatives as Anticancer Agents
Tomeh, M. A., Hadianamrei, R., & Zhao, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051033 · Cited by 949
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges
Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., Pandey, A., Garg, V. K., Sethi, G., & Bishayee, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.014 · Cited by 390
Cyclodextrin–Drug Inclusion Complexes: In Vivo and In Vitro Approaches
Carneiro, S., Costa Duarte, F., Heimfarth, L., Siqueira Quintans, J., Quintans-Júnior, L., Veiga Júnior, V., & Neves de Lima, Á. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030642 · Cited by 350
Cyclodextrins: Structural, Chemical, and Physical Properties, and Applications
Poulson, B. G., Alsulami, Q. A., Sharfalddin, A., El Agammy, E. F., Mouffouk, F., Emwas, A.-H., Jaremko, L., & Jaremko, M. (2021) · Polysaccharides · doi:10.3390/polysaccharides3010001 · Cited by 312
Contact Lens Technology: From Fundamentals to Applications
Moreddu, R., Vigolo, D., & Yetisen, A. K. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900368 · Cited by 264
Alambiaga-Caravaca, A. M., Calatayud-Pascual, M. A., Rodilla, V., Concheiro, A., López-Castellano, A., & Alvarez-Lorenzo, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080702 · Cited by 38
“The remarkable advantages of PG encapsulation in the prepared polymeric micelles compared to the inclusion complex formation with cyclodextrins rely on: (i) The outstanding 100% encapsulation efficiency in micelles, which is never reached with cyclodextrins; (ii) the higher thermodynamic and kinetic stability of the m…”
BackgroundÜnal, S., Can Öztürk, S., Bilgiç, E., Yanık, H., Korkusuz, P., Aktaş, Y., Benito, J. M., Esendağlı, G., & Bilensoy, E. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.10.010 · Cited by 25
Metadata
- Authors
- Gidwani, B., & Vyas, A.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-15
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2149107062
- Cited by
- 473
- References
- 82
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.